The global genetic testing market size was USD 19.60 billion in 2023, estimated at USD 21.89 billion in 2024 and is anticipated to reach around USD 65.03 illion by 2034, expanding at a CAGR of 11.50% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Genetic Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Genetic Testing Market, by Test Type, 2024-2034
8.1.1. Carrier Testing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Predictive Testing
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Diagnostic Testing
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Prenatal & Newborn Testing
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Nutrigenomics
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Pharmacogenomics
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2034)
9.1. Genetic Testing Market, by Disease, 2024-2034
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Alzheimer’s
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Thalassemia
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Cystic Fibrosis
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Huntington’s Disease
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Duchenne Muscular Dystrophy
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Test (2021-2034)
10.1.2. Market Revenue and Forecast, by Disease (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Disease (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test (2021-2034)
10.2.2. Market Revenue and Forecast, by Disease (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Disease (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Disease (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Disease (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Disease (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Disease (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Disease (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.4.2. Market Revenue and Forecast, by Disease (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Disease (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Disease (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Disease (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test (2021-2034)
10.5.2. Market Revenue and Forecast, by Disease (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Disease (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Disease (2021-2034)
11.1. Genentech Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Sorenson Genomics, LLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Molecular
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer Diagnostics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Biocartis
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. BioHelix
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Celera Genomics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Genomic Health
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. HTG Molecular Diagnostics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. PacBio
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample